Abstract
Squamous cell carcinoma of the head and neck, SCCHN, is a heterogeneous group of tumours not only concerning the site of origin but also regarding aetiology. The 5-year survival for the whole group of SCCHN tumours has not significantly improved over the last 20-25 years. Apart from tumour spread to lymph nodes, N status, gains and losses of specific chromosomes are the only factors shown to be independent prognostic markers for these tumours. Worldwide, an increasing number of people ≤ 40 years are seen being affected by tongue SCC, the most common tumour within the SCCHN group. Even without any clinical signs of metastasis, up to 30% of all tongue SCC have histologically detectable spread to lymph nodes.
In this mini review, field cancerization, tumour microenvironment, the so called EMT (epithelial mesenchymal transition) process and the role of viruses in development of SCCHN are discussed as well as potential new therapeutic targets.
For the group of tongue SCC, with the increasing incidence seen in young patients and particularly women, new data with impact on prognosis and treatment are urgently needed. But as long as data from the analyses of several sub sites are presented as valid for the whole group of tumours, this vital point is missed.
Keywords: Squamous cell carcinoma, Tongue, Prognosis, Therapy, miRNA, HPV, EBV, p63.
Current Topics in Medicinal Chemistry
Title:Searching for New Targets and Treatments in the Battle Against Squamous Cell Carcinoma of the Head and Neck, with Specific Focus on Tumours of the Tongue
Volume: 18 Issue: 3
Author(s): Nicola Sgaramella*, Xiaolian Gu, Linda Boldrup, Philip J Coates, Robin Fahraeus, Luigi Califano, Gianpaolo Tartaro, Giuseppe Colella, Lena Norberg Spaak, Adrian Strom, Torben Wilms, Lorenzo Lo Muzio, Giovanni Dell`Aversana Orabona, Mario Santagata, Lotta Loljung, Riccardo Rossiello, Karin Danielsson, Klas Strindlund, Sandra Lillqvist and Karin Nylander*
Affiliation:
- Department of Medical Biosciences, Umea University, Umea,Sweden
- Department of Medical Biosciences, Umea University, Umea,Sweden
Keywords: Squamous cell carcinoma, Tongue, Prognosis, Therapy, miRNA, HPV, EBV, p63.
Abstract: Squamous cell carcinoma of the head and neck, SCCHN, is a heterogeneous group of tumours not only concerning the site of origin but also regarding aetiology. The 5-year survival for the whole group of SCCHN tumours has not significantly improved over the last 20-25 years. Apart from tumour spread to lymph nodes, N status, gains and losses of specific chromosomes are the only factors shown to be independent prognostic markers for these tumours. Worldwide, an increasing number of people ≤ 40 years are seen being affected by tongue SCC, the most common tumour within the SCCHN group. Even without any clinical signs of metastasis, up to 30% of all tongue SCC have histologically detectable spread to lymph nodes.
In this mini review, field cancerization, tumour microenvironment, the so called EMT (epithelial mesenchymal transition) process and the role of viruses in development of SCCHN are discussed as well as potential new therapeutic targets.
For the group of tongue SCC, with the increasing incidence seen in young patients and particularly women, new data with impact on prognosis and treatment are urgently needed. But as long as data from the analyses of several sub sites are presented as valid for the whole group of tumours, this vital point is missed.
Export Options
About this article
Cite this article as:
Sgaramella Nicola *, Gu Xiaolian, Boldrup Linda, Coates J Philip, Fahraeus Robin , Califano Luigi , Tartaro Gianpaolo, Colella Giuseppe , Spaak Norberg Lena , Strom Adrian , Wilms Torben , Muzio Lo Lorenzo, Orabona Dell`Aversana Giovanni , Santagata Mario, Loljung Lotta , Rossiello Riccardo, Danielsson Karin , Strindlund Klas , Lillqvist Sandra and Nylander Karin *, Searching for New Targets and Treatments in the Battle Against Squamous Cell Carcinoma of the Head and Neck, with Specific Focus on Tumours of the Tongue, Current Topics in Medicinal Chemistry 2018; 18 (3) . https://dx.doi.org/10.2174/1568026618666180116121624
DOI https://dx.doi.org/10.2174/1568026618666180116121624 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nitric Oxide in Cancer Therapeutics: Interaction with Cytotoxic Chemotherapy
Current Pharmaceutical Design Long-Term Safety from the Raltegravir Clinical Development Program
Current HIV Research p53: Fighting Cancer
Current Cancer Drug Targets Photodynamic Therapy For Non-Melanoma Skin Cancers
Current Cancer Therapy Reviews HPV Infection and Intraepithelial Lesions: Comparison Between HIVPositive and Negative Women
Current HIV Research Carbon Nanotubes in the Diagnosis and Treatment of Malignant Melanoma
Anti-Cancer Agents in Medicinal Chemistry From 2D to 3D - a New Dimension for Modelling the Effect of Natural Products on Human Tissue
Current Pharmaceutical Design Prostate Cancer Prevention by Silibinin
Current Cancer Drug Targets Interaction Between Retinoids and Eicosanoids: Their Relevance to Cancer Chemoprevention
Current Nutrition & Food Science Bronchial Asthma and Lung Cancer
Current Respiratory Medicine Reviews Evaluation of Non-Coding RNAs as Potential Targets in Head and Neck Squamous Cell Carcinoma Cancer Stem Cells
Current Drug Targets Melanoma
Current Cancer Therapy Reviews PiWi RNA in Neurodevelopment and Neurodegenerative Disorders
Current Molecular Pharmacology Viral Origins of Human Cancer
Current Medicinal Chemistry Gold Nanoparticles - Synthesis and Applications in Cancer Management
Recent Patents on Materials Science Mitochondrial DNA Mutations in Cancer: A Review
Current Topics in Medicinal Chemistry Animal Modeling of Cancer Pathology and Studying Tumor Response to Therapy
Current Drug Targets Tobacco, Inflammation, and Respiratory Tract Cancer
Current Pharmaceutical Design Chemoradiotherapy in Locally Advanced, Unresectable Non-Small Cell Lung Cancer
Reviews on Recent Clinical Trials Upregulated Long Non-coding RNA ALMS1-IT1 Promotes Neuroinflammation by Activating NF-κB Signaling in Ischemic Cerebral Injury
Current Pharmaceutical Design